These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-001674-80 A Randomised, Open, Parallel Group, Multicentre Study to Examine the Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Combination with Clopidogrel and Aspirin in Patients unde... 2006-10-04 due-trials
Reported results 2005-004989-17 A PHASE III, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF AST-120 FOR PREVENTION OF CHRONIC KIDNEY DISEASE PROGRESSION IN PATIENTS WITH MODERATE TO SEVERE CHRONIC KIDNEY DISEASE 2013-05-09 due-trials
Reported results 2005-004990-13 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease including Ass... 2011-10-18 due-trials
Not reported 2005-005457-22 A phase IIa, multi-centre, randomised, placebo-controlled, double-blind, parallel group study of TA-5538, in patients with overactive bladder 2007-01-18 due-trials
Reported results 2006-003323-37 A Phase III, Randomised, Double-blind, Multi-centre, Withdrawal Study comparing MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (Incorporatin... 2009-11-11 due-trials
Reported results 2006-003324-11 A Phase III, Double-blind, Multi-centre, Randomised, Parallel Group Design, Placebo-controlled, Flexible Dose Study of MCI-196 in Combination with a Calcium-based Phosphate Binder in Chronic Kidney Di... 2010-01-07 due-trials
Reported results 2006-003330-15 A Phase III, Multicentre, Open Label, Flexible dose, Long term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (incorporating a Comparison with S... 2010-08-06 due-trials
Reported results 2006-006535-53 A Phase III, Multi-centre, Double-blind, Randomised, Placebo-controlled, Multiple Fixed-dose Study of MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphatae... 2009-11-12 due-trials
Reported results 2007-003364-21 A Phase III, Multicentre, Double-blind, Double-Dummy, Randomised, Flexible-dose, Comparative Study of MCI-196 versus Simvastatin for the Treatment of Dyslipidaemia in Subjects with Chronic Kidney Dise... 2010-03-20 due-trials
Reported results 2008-000730-42 An open-label, multi-centre, clinical study to collect information on the clinical use of argatroban in patients with heparin induced thrombocytopenia (HIT) Type II who require parenteral antithrombot... 2011-02-02 due-trials
Reported results 2008-003397-17 A Phase IIa, multi-centre, randomised, double-blind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of a n... 2010-11-05 due-trials
Reported results 2008-008732-84 A Phase IIb, double-blind, parallel group, multi-centre, dose-finding study to investigate the efficacy and safety of 4 doses of MP-513 when added to ongoing metformin monotherapy in subjects with Typ... 2011-04-14 due-trials
Reported results 2012-002470-31 A phase II, multicentre, randomised, double-blind, parallel group, placebo-controlled, dose-finding study to evaluate the safety and efficacy of three different oral doses of MT-1303 administered for ... 2014-10-23 due-trials
Reported results 2012-002480-98 A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral Do... 2014-09-30 due-trials
Reported results 2012-002481-12 A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral Do... 2014-09-15 due-trials
Reported results 2012-002581-12 A Multi-centre, Randomised, Controlled, Parallel Group, Open-label Study Evaluating the Efficacy, Safety and Tolerability of Three Doses of Colestilan (MCI-196) Compared to Standard Therapy with a Cal... 2015-01-26 due-trials
Reported results 2012-002582-35 A Multi-centre, Open-label Study Evaluating the Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects with Chronic Kidney Disease Stages 3b to 5 and with Hyperphosphataemia not on Dia... 2014-12-17 due-trials
Completed, but no date, and reported results Terminated 2012-002583-27 A Multi-centre, Flexible Dose, Parallel Group, Open-label, Active Control (Calcium-based Phosphate Binder), Long-term Extension Study Evaluating the Efficacy, Safety and Tolerability of Colestilan (MC... bad-data
Reported results 2012-002639-27 A phase II, multicentre study to evaluate the long-term safety and efficacy of MT-1303 in subjects with relapsing-remitting multiple sclerosis who have completed the MT-1303-E04 study Studio multic... 2016-03-15 due-trials
Reported results 2012-005750-27 A Phase IIa, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT-1303 in Subjects with Moderate to Severe Chron... 2014-11-21 due-trials
Reported results 2014-002556-77 A Phase II, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT 1303 in Subjects with Moderate to Severe Active... 2016-10-10 due-trials
Reported results 2014-002557-19 A Phase II, Open-label, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects with Moderate to Severe Active Crohn’s Disease who have Completed the MT-1303-E13 Study 2017-08-24 due-trials
Reported results 2016-002571-10 A Phase IIa, Multi-Centre, Randomised, Double-Blind, Cross-Over, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of MT-8554 in Subjects with Painful Diabetic Peripheral Neurop... 2018-08-08 due-trials
Reported results 2016-003521-42 SAICoDis – Safety of Argatroban Infusion in Conduction Disturbances. A prospective, open, multicenter safety study to investigate conduction disturbances in patients receiving argatroban therapy. 2021-05-12 due-trials
Reported results 2019-002108-41 A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS) 2021-10-07 due-trials
Listed as ongoing, but also has a completion date and reported results 2019-004226-16 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X-L... 2022-07-27 bad-data
Completed, report not yet due 2019-004256-11 A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS) 2023-09-29 not-yet-due
Other 2020-000134-17 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Diffuse Cutaneous Systemic Scleros... not-yet-due
Listed as ongoing, but also has a completion date 2020-000376-38 A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered over 96 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS) 2023-08-09 bad-data
Other 2021-001831-17 A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Prot... not-yet-due
Completed, report not yet due Terminated 2021-003900-42 A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Stud... 2023-09-22 not-yet-due

Related organisations

Over time organisations can merge, or split.

We think Mitsubishi Tanabe Pharma Corporation is now also responsible for the trials of: